Compare JFIN & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | LENZ |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 278.4M |
| IPO Year | 2018 | 2021 |
| Metric | JFIN | LENZ |
|---|---|---|
| Price | $4.89 | $9.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 40.7K | ★ 664.0K |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $8.25 |
| 52 Week High | $18.70 | $50.19 |
| Indicator | JFIN | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 44.15 |
| Support Level | $3.70 | $8.99 |
| Resistance Level | $5.00 | $10.34 |
| Average True Range (ATR) | 0.21 | 0.59 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 83.19 | 31.52 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.